(MENAFNEditorial)
Supported by strong democratic institutions and a long history of stable political Leadership Canada is home to t he second largest pharmaceutical market in the Americas and one of the largest in world . We believe that drugmakers will continue to realise considerab le rewards as sales of patented pharmaceuticals settle into a trend of steady growth which is only nominally affected by the particularly slow penetration of generics. However drugmakers will find their interests threatened by the potential for a sharp correction in private consumption which has been made increasingly fragile by high household debt a weaker Canadian dollar and expectations of t ightening of credit conditions once the Bank of Canada begins to raise interest rates .
Full Report Details at
- http://www.fastmr.com/prod/957404_canada_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=101
Headline Expenditure Projections
* Pharmaceuticals: CAD22.93bn (USD20.75bn) in 2014 to CAD23.62bn (USD19.68bn) in 2015; +3.0% in local currency terms and -5.2% in US dollar terms. Forecast revised upwards from Q115 .
* Healthcare: CAD211.92bn (USD191.85bn) in 2014 to CAD220.60bn (USD183.84bn) in 2015; +4.1% in local currency terms and -4.2% in US dollar terms. Forecast revised downwards from Q115 .
Risk/Reward Index
Canada scores 71.1 out of 100 in BMI's Pharmaceuticals & Healthcare Risk/Reward Index up from Q115 and retaining its position as the second-most attractive pharmaceutical market in the Americas region behind the US.
Key Trends A nd Developments
* In January 2015 the Fraser Institute announced an increase in median waiting times for treatment in Canada to 18.2 weeks up from 9.3 for the same procedure in 1993. The average waiting time in Alberta in Canada from the date of a specialist booking to actual surgery was 85 days compared with the national average of 49 days according to the Canadian Institute for Health Information. On December 15 2011 Alberta Health Services announced the Expedited Management of Lung Cancer Programme which aimed to ensure that by...
The Canada Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Canada Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Canada pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Canada to test other views - a key input for successful budgeting and strategic business planning in the Canadian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Canadian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Canada.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.